Skip to main content
. 2018 Jan 1;8(1):92–108. doi: 10.7150/thno.21074

Figure 5.

Figure 5

T1-T2 dual mode MR imaging of U87MG tumor-bearing mice (n = 3) with Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs in vivo. (A) Representative in vivo T1- and T2-weighted MR images of mice following i.v. administration of Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG NPs and Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs at different time points. (B, C) Quantitative analysis of T1- and T2-weighted MR images tumor contrast enhancement after i.v. injection of Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG NPs and Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs. The average MR relative T1 and T2 signal enhancements were measured for each tumor. The higher contrast of tumor positions by Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs may result from the active targeting effect of tumor-penetrating peptide RGERPPR.